Table 2.
Characteristics of 5-FU-loaded PLGA nanospheres from previous studies
| Fabrication method |
PLA:PGA ratio |
Organic phase |
Surfactant | Diameter (nm±SD) |
Encapsulation efficiency (%) |
Loaded drug amount (mg/mg) |
Release duration (hours) |
Route of administration |
Ref |
|---|---|---|---|---|---|---|---|---|---|
| Double emulsion-solvent evaporation* | 75:25 | Acetic ether | Poloxamer 188 | 81.4–87.7 | 64 | 0.13 | 288 | Oral | 70 |
| Emulsion-solvent evaporation* | 50:50 | Acetone | Lutrol F68 | 117.8 ± 15.6 | 59.1 | 0.0439 | 120 | - | 85 |
| Double emulsion-solvent evaporation* | 50:50 | DCM | Pluronic F-68 | 150 | 66.6 | - | 168 | - | 101 |
| Double emulsion-solvent evaporation* | 90:10 | DCM | Pluronic F-68 | 190 | 65.5 | - | 168 | - | 101 |
| Double emulsion-solvent evaporation | 50:50 | DCM | PVA | 185–300 | 17.13–38.37 | 0.024–0.068 | 120 | - | 185 |
| Double emulsion-solvent evaporation | 85:15 | DCM | PVA | 126.9 ±64.3 | 8 | - | 360 | IV | 119 |
| Double emulsion-solvent evaporation | 50:50 | DCM | Pluronic F-68 | 100–200 | 0.7313 | 0.2023 | 2.5 | - | 186 |
*
PdI are provided.
Abbreviations: IV - intravenous; DCM – dichloromethane; PVA - polyvinyl alcohol; PLA – polylactic acid; PGA – polyglycolic acid